Welcome to our dedicated page for Savara SEC filings (Ticker: SVRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Savara Inc. filings document a clinical-stage biopharmaceutical issuer focused on rare respiratory diseases and its development of molgramostim inhalation solution for autoimmune pulmonary alveolar proteinosis. The record includes Nasdaq-listed common stock disclosures, Regulation FD corporate presentations, clinical and regulatory updates, operating and financial results, and material-event reports tied to business operations.
Recent filings also cover definitive proxy materials, board and compensation matters, shareholder voting matters, lease obligations, and debt arrangements under a loan and security agreement. These disclosures describe Savara's capital structure, financing covenants, material agreements, governance practices and corporate reporting obligations.
Savara Inc reported that Chief Fin. & Operating Officer Robert Matthew Lutz received equity awards on July 15, 2026. He was granted 35,000 restricted stock units that vest in full on July 15, 2028, subject to continued service, and options for 70,000 shares at an exercise price of $5.81 per share, vesting in 16 equal quarterly installments starting July 15, 2026. Following these grants, he directly holds 328,977 shares of common stock and 70,000 stock options.
Savara Inc Chief Financial Officer David L. Lowrance reported a combined option exercise and share sale in Savara common stock. On June 22, 2026, he sold 394,528 shares in an open-market transaction at a weighted average price of $5.6813 per share, with sale prices ranging from $5.54 to $5.78. On the same date, he exercised stock options covering a total of 580,187 shares at exercise prices between $1.11 and $4.45 per share, and 185,659 shares were withheld to satisfy tax obligations. Following these transactions, Lowrance directly owned 536,032 shares of Savara common stock.
Savara Inc. reported that stockholders approved key corporate changes and an executive transition. They amended the 2024 Omnibus Incentive Plan to add authorization for 18,900,000 additional shares of common stock for equity awards. Stockholders also approved a charter amendment doubling authorized common shares from 300,000,000 to 600,000,000, which became effective upon filing in Delaware.
The Board appointed Robert Lutz as Chief Financial and Operating Officer effective July 15, 2026, following the health-related resignation of current Chief Financial and Administrative Officer David Lowrance. Lutz will receive a $510,000 base salary, a stock option for 70,000 shares vesting quarterly over four years, and 35,000 restricted stock units vesting after two years. Lowrance will receive severance under his employment agreement, partial vesting acceleration, and is expected to serve as a consultant at $200 per hour. Stockholders also re-elected all director nominees and approved other proposals at the annual meeting.
Savara Inc. reported a net loss of $37.3M for the quarter ended March 31, 2026, wider than $26.6M a year earlier, driven by higher research and development and stock-based compensation. R&D expenses rose to $23.4M and general and administrative costs to $15.6M.
The company ended the quarter with $38.8M in cash and cash equivalents and $164.0M in short-term investments, supporting continued development of MOLBREEVI for autoimmune PAP. The FDA has filed the Biologics License Application, granted Priority Review, and extended the PDUFA date to November 22, 2026, while EMA and MHRA have validated marketing applications in Europe and the U.K.
Savara Inc. is asking stockholders to approve several items at its 2026 virtual annual meeting while advancing its lead drug candidate MOLBREEVI for autoimmune pulmonary alveolar proteinosis. Regulatory reviews are underway in the U.S., EU, and UK, including an FDA Priority Review with an action date of November 22, 2026.
The company highlights recent financing actions: a $149.5 million equity raise, a $75 million royalty funding agreement with RTW, and an amended debt facility allowing up to $75 million of additional funding upon FDA approval. Proposals include electing six directors, doubling authorized common shares from 300,000,000 to 600,000, increasing the 2024 Omnibus Incentive Plan share pool by 18,900,000, ratifying RSM US LLP as auditor, and holding an advisory vote on executive pay.
Savara Inc. is soliciting proxies for its 2026 Annual Meeting to be held virtually on June 4, 2026, asking stockholders to elect six directors and vote on corporate governance and compensation proposals.
The company highlights regulatory milestones for its investigational therapy MOLBREEVI: an FDA Priority Review action date of August 22, 2026, an EU decision expected in Q1 2027, and a UK decision expected in Q4 2026. Savara reports it completed a $149.5 million equity financing, entered a $75 million royalty funding agreement, and amended a debt facility to permit up to $75 million additional debt funding upon FDA approval.
Key votes include approval to increase authorized common shares from 300,000,000 to 600,000,000, an 18,900,000-share increase to the 2024 Omnibus Incentive Plan, ratification of RSM US LLP as auditor, and an advisory vote on executive compensation. Shares outstanding were 204,922,140 as of April 6, 2026.
Savara Inc Chief Financial Officer David L. Lowrance exercised several stock option grants on March 18, 2026, acquiring a total of 366,747 shares of Common Stock through option exercises at strike prices ranging from $1.11 to $4.45 per share. To cover exercise costs and tax obligations, 116,760 shares of Common Stock were withheld by the issuer in transactions coded as F, which are tax-withholding dispositions rather than open‑market sales. Following these transactions, Lowrance directly owned 536,032 shares of Savara common stock. The derivative transactions reflect routine option exercises tied to grants that vest in quarterly installments, as described in the footnotes.
Savara Inc. entered into a new headquarters lease with ML7 Yardley Partners, LP for approximately 10,795 square feet of office space at 19 W. College Avenue, Suite 200, Yardley, Pennsylvania. The lease term begins on July 1, 2026 and runs through December 1, 2031, with an option to extend for an additional five years.
Savara will pay monthly base rent of about $28,337 in the first year, with annual increases of roughly 2%. Aggregate base rent over the term is approximately $1,780,900, reflecting five months of rent abatement. The company will also pay its share of operating expenses, taxes, and utilities and has provided a $28,337 security deposit.